Delivery Order SPE2DB20D1109-SPE2DB21FP58S

Award Date 7/14/21
Potential Completion Date 7/15/21
Potential Value $8.7K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of Vyvanse 50 mg capsules to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $2,231.10, is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, valued at up to $999,999,999.00, serves as the primary...
This federal contract award is for the delivery of Vyvanse 20 mg capsules to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,081.35, is a delivery order awarded under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, valued at up to $999,999,999.00, serves as the...
This federal contract award is for the delivery of Vyvanse 20 mg capsules to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order valued at $2,586.06 and has a completion date of December 3, 2021. The contract is part of a larger Indefinite Delivery Contract (IDC) between Cencora, Inc. (doing business as Amerisourcebergen) and the DLA Troop Support Medical,...
The federal contract award is for the delivery of 10 mg Vyvanse capsule medication to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is a firm fixed price delivery order with a potential value of $3,202.89 and a completion date of March 7, 2024. The contract does not have a set-aside designation. Amerisourcebergen Drug...
This federal contract award from the Defense Logistics Agency (DLA) is for the delivery of Vyvanse 50 mg capsules to the U.S. government. The prime contractor is Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, one of the largest pharmaceutical distribution companies. This Delivery Order contract, valued at $3,613.72, has a firm fixed price and an ultimate completion date of May 15, 2024. The contract is not set aside for any special designation. Amerisourcebergen Drug...
This federal contract award is for the delivery of Vyvanse 50 mg capsules to the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $1,372.34, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under a broader Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a primary...
This federal contract award is for the delivery of Vyvanse 30mg capsules, a prescription medication, to the Defense Logistics Agency (DLA) Troop Support Medical. The $2,071.61 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. This contract is a part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, which enables the company to supply a comprehensive...
This federal contract award, issued by the Defense Logistics Agency (DLA), is a delivery order valued at $1,468.54 for the pharmaceutical product Vyvanse 10 mg capsules. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. This award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen holds with the DLA Troop Support Medical, running through November 2026. This IDC...
This federal contract award is for the delivery of Vyvanse 20 mg capsules to the Defense Logistics Agency (DLA). The contract was awarded to the prime contractor, Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $1,337.70 and is a firm fixed-price delivery order with a completion date of February 5, 2025. The contract is not designated with a set-aside. Amerisourcebergen Drug Corp holds a significant Indefinite...
This federal contract award is for the delivery of Vyvanse 30 mg capsules in 100-count packages to the Defense Logistics Agency (DLA). The $9,748.40 firm-fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on October 21, 2024, with an ultimate completion date of October 22, 2024. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with...
  • SPE2DB20D1109
    Indefinite Delivery Contract
  • SPE2DB20D1109-SPE2DB21FP58S
    Delivery Order

This federal contract award is for the delivery of Vyvanse 20 mg capsules to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,688.04, is a delivery order awarded under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a potential value of up to $999,999,999 and runs through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen's parent company is Cencora, Inc., which also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.

Generated 2/27/25, 1:26 PM